theralase_logo_destroying_cancer.png
Theralase® Phase Ib NMIBC Clinical Study Published
June 21, 2022 07:00 ET | Theralase Technologies Inc.
TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
theralase_logo_destroying_cancer.png
Theralase Releases Q122 Interim Financial Statements
May 30, 2022 17:53 ET | Theralase Technologies Inc.
TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
theralase_logo_destroying_cancer.png
Theralase Release FY2021 Audited Financial Statements
April 29, 2022 21:11 ET | Theralase Technologies Inc.
TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Bladder Cancer Detection Kit Market Size Worth USD 322 Million by 2027 at 11.17% CAGR - Report by Market Research Future (MRFR)
April 26, 2022 15:47 ET | WantStats Research and Media Pvt. Ltd.
New York, US, April 26, 2022 (GLOBE NEWSWIRE) -- Bladder Cancer Detection Kit Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Bladder Cancer...
22157.jpg
Global Immune Checkpoint Inhibitors Market to 2027 - Size, Share & Industry Trends Analysis Report
April 26, 2022 06:43 ET | Research and Markets
Dublin, April 26, 2022 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma,...
theralase_logo_destroying_cancer.png
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
April 05, 2022 07:00 ET | Theralase Technologies Inc.
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Vantage Market Research.png
Antibody Drug Conjugates (ADCs) Market Size to Reach USD 13.17 Billion by 2028 - Powered by Approval for Biologics License Applications – Vantage Market Research
February 15, 2022 04:39 ET | Vantage Market Research
WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Antibody Drug Conjugates (ADCS) Market finds that granted accelerated approval for biologics...
Cancer Support Commu
Cancer Support Community Launches New Study Focused on Bladder Cancer
February 10, 2022 16:25 ET | Cancer Support Community
PHILADELPHIA, PA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC), the world’s largest provider of cancer support with a network of 175 locations across the United States and...
Logo.png
Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight
January 31, 2022 13:00 ET | DelveInsight Business Research LLP
Las Vegas, USA, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight  Non-Muscle Invasive Bladder Cancer Pipeline...
22157.jpg
Worldwide Immuno Oncology Assays Industry to 2026 - Clinical Trials to Cure Different Cancers in Immunotherapy Presents Opportunities
January 05, 2022 06:38 ET | Research and Markets
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Immuno Oncology Assays Market Research Report by Indication, Product, Technology, Application, and Region - Global Forecast to 2026 - Cumulative Impact...